Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer

Completed

• Conditions: Gastric Cancer Stage IV

• Registration Number: NCT07009600
• Lead Sponsor: Samsung Medical Center

Brief Summary

In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery. Specifically, investigators examined the impact of targeted therapy or immune check point inhibitors (ICIs) in combination with preoperative chemotherapy on (1) prognostic differences based on initial progression (invading adjacent organs) and metastatic site (peritoneum, distant lymph node \[LN\]) at the time of stage IV gastric cancer diagnosis and (2) conversion surgery outcomes and pathological complete response (pCR).

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01-01
• Primary Completion: 2024-12-31
• Study Completion: 2024-12-31
• Study First Submitted: 2025-05-23
• Status Verified: 2025-06
• Study First Submitted QC: 2025-06-03
• Last Update Submitted: 2025-06-03
• Study First Posted: 2025-06-06
• Last Update Posted: 2025-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

• Stage IV gastric cancer patients who underwent conversion surgery

Exclusion Criteria

• Patients who did not undergo gastrectomy
• Patients who underwent emergent surgery due to cancer perforation
• Patients with missing medical records or information

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
overall survival and disease free survival	from date of surgery until the date of first documented cancer recurrence or date of death from cancer progression, whichever came first, assessed up to 160 months